熱門資訊> 正文

DexCom的OTC CGM Stello获得儿科批准

2026-06-13 04:20

德康醫療(DXCM) 0

The US FDA has approved DexCom's (DXCM) over-the-counter continuous glucose monitor Stelo for use in children two years and older.
The indication is for children who receive oral medication for diabetes.
Stelo consists of a wearable sensor that is paired to a smartphone app that tracks and provides glucose data every 15 minutes. The sensor is replaced every 15 days.
Stelo is the first OTC CGM approved for children.

More on DexCom

DexCom: A Medical Platform Play Gaining From AI, Not Disrupted By It
DexCom Might Finally Be Cheap Enough
DexCom, Inc. (DXCM) Analyst/Investor Day - Slideshow
DexCom says some CGM sensors intended for scrap stolen and resold
Chip stocks lead Nasdaq's gainers this week; Intuit plunges most after Q3 print

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。